Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
1e5 of Mouse Anti-CD4 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA2H7) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
1e5 of Mouse Anti-CD4 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA2H7) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
Immobilized Alexa Fluor 647-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA2H8) at 1 μg/mL (100 μL/well) can bind Anti-CD4 Antibody (Ibalizumab-IgG4) with a linear range of 0.1-8 ng/mL (Routinely tested). Labeling with fluorescent dyes did not affect their activity.
The purity of Biotinylated Rhesus macaque CD4,His,Avitag (Cat. No. CD4-R82E3) is more than 90% and the molecular weight of this protein is around 43-53 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ibalizumab | Hu5A8; TMB-355; TNX-355; 5AB | Approved | Biogen Inc | 特罗格佐, Trogarzo | EU | HIV Infections | Theratechnologies Europe Ltd | 2018-03-06 | HIV Infections | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CALRLong36 peptide (Herlev Hospital) | Phase 1 Clinical | Herlev Hospital | Myeloproliferative Disorders | Details | |
| CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
| TMB-365 | TMB-365 | Taimed Biologics Inc | Details | ||
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Umoja BioPharma Inc | Details | ||
| IMCY-0141 | IMCY-0141 | Imcyse Sa | Details | ||
| Anti-CD4 CAR T-cell therapy (University of Pennsylvania) | CAR-C34ZFN | University Of Pennsylvania | Details | ||
| RB-0003 | RB-0003; BNT-111 | Biontech Se, Tron | Details | ||
| Tregalizumab | hB-F5; BT-061 | Phase 2 Clinical | Biotest Pharma Gmbh | Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma | Details |
| Mosedipimod | EC-18 | Phase 2 Clinical | Enzychem Lifesciences Co | Neutropenia; Coronavirus Disease 2019 (COVID-19); Stomatitis; Febrile Neutropenia | Details |
| IT-1208 (Kyowa Hakko Kirin) | IT-1208 | Phase 1 Clinical | Kyowa Hakko Kirin Co Ltd | Neoplasms | Details |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| VRC-07-523 | VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral | Details |
| VRC-01-LS | VRC-HIVMAB-080-00-AB; VRC-01-LS | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| 10E8.4/iMab (Aaron Diamond AIDS Research Center) | TMB-370 | Phase 1 Clinical | Aaron Diamond Aids Research Center For The City Of New York, Inc | HIV Infections | Details |
| T-allo-10 | T-allo-10 | Phase 1 Clinical | Stanford University | Hematologic Diseases; Graft vs Host Disease | Details |
| CD4 CAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Lymphoma, T-Cell | Details | ||
| CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) | CD4CAR (Icell Gene) | Phase 1 Clinical | Stony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of Louisville | Lymphoma, T-Cell; Leukemia, T-Cell | Details |
| Autologous Regulatory Т-cell Therapy | Phase 2 Clinical | Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus | Scleroderma, Systemic | Details | |
| VRC-HIVMAB091-00-AB | N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| LB-1901 | LB-1901; LB1901 | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous | Details |
| VRC-HIVMAB0115-00-AB | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| Semzuvolimab | dB4; UB-421; mAb-B4 | Phase 3 Clinical | United Biomedical Inc | HIV Infections | Details |
| ITV 1(Nonindustrial source) | ITV-1 | Phase 3 Clinical | Synexa Life Sciences, Immunotech Laboratories, Nonindustrial Source | HIV Infections | Details |
This web search service is supported by Google Inc.
A-Z
